Pascal Biosciences Inc (CVE:PAS) shares traded down 5% on Thursday . The stock traded as low as C$0.19 and last traded at C$0.19, 15,900 shares changed hands during trading. A decline of 69% from the average session volume of 51,455 shares. The stock had previously closed at C$0.20.
The firm’s 50-day moving average is C$0.17 and its two-hundred day moving average is C$0.21. The stock has a market cap of $10.00 million and a price-to-earnings ratio of -2.21.
Pascal Biosciences Company Profile (CVE:PAS)
Pascal Biosciences Inc, a drug discovery and development company, researches and develops biotechnology products for the treatment of cancer and for the enhancement of immune system in Canada. Its research programs include the development of Anti-VpreB, a therapeutic monoclonal antibody for treatment of B-cell precursor acute lymphoblastic leukemia in collaboration with the University of New Mexico; optimization of novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Pascal Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pascal Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.